DEFA14A: Catheter Precision Issues Placement Agent Warrant Tied to Recent PIPE Financing

Catheter Precision, Inc. has approved the issuance of a common stock purchase warrant to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to its May 2025 PIPE financing, pending stockholder approval.

Summary

• Catheter Precision, Inc.'s Board of Directors approved the issuance of a placement agent common stock purchase warrant to Ladenburg Thalmann & Co., Inc. on June 5, 2025.
• The warrant allows the holder to acquire 257,143 shares of Company common stock.
• The purchase price (exercise price) for the shares is $0.5425 per share.
• This warrant serves as partial compensation for services provided by Ladenburg Thalmann & Co., Inc. in connection with the Company's pipe financing that closed on May 12, 2025.
• The warrant will become exercisable only upon approval by the Company's stockholders.
• The Company anticipates seeking this stockholder approval at its annual meeting scheduled for July 25, 2025.
• The warrant is set to terminate on June 6, 2030.
• Neither the warrant nor the underlying shares have been registered under the Securities Act of 1933, as amended.

Sentiment

Score: 5

Explanation: The document is largely factual regarding a corporate action (warrant issuance as compensation). While it introduces potential future dilution, it's a standard mechanism for compensating placement agents for past financing services, making the overall sentiment neutral.

Positives

• The issuance of the warrant serves as compensation for investment banking services, fulfilling obligations related to a recent financing.
• It potentially aligns the interests of the placement agent with the Company's future stock performance.

Negatives

• The exercise of the warrant, if approved and executed, will result in dilution for existing shareholders by increasing the number of outstanding common shares.
• The exercisability of the warrant is contingent upon stockholder approval, introducing an element of uncertainty.

Risks

• Shareholder non-approval: If stockholders do not approve the exercise of the warrant at the annual meeting, the warrant may not become exercisable, potentially impacting the compensation arrangement with the placement agent.
• Dilution: The potential issuance of 257,143 new common shares upon exercise of the warrant could dilute the ownership percentage of current shareholders.
• Unregistered securities: The warrant and its underlying shares are not registered under the Securities Act of 1933, which imposes restrictions on their resale.

Future Outlook

The exercisability of the warrant is contingent upon stockholder approval at the annual meeting on July 25, 2025. If approved, the warrant will be exercisable until June 6, 2030.

Industry Context

N/A

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution if the warrant is approved and subsequently exercised, as it would increase the total number of outstanding common shares.
• Ladenburg Thalmann & Co., Inc. (Placement Agent): Will receive 257,143 common stock purchase warrants as compensation, contingent on shareholder approval, which could provide future equity upside.

Next Steps

• The Company intends to file and mail a definitive proxy statement to stockholders for the 2025 Annual Meeting.
• Stockholders will vote on the approval of the warrant exercise at the annual meeting on July 25, 2025.

Key Dates

Keywords

Catheter Precision, VTAK, Warrant, Common Stock, PIPE Financing, Ladenburg Thalmann & Co. Inc., SEC Filing, Stockholder Approval, Equity Compensation, Dilution